新型冠状病毒肺炎患者肝损伤机制研究进展*

doi:10.3969/j.issn.1672-5069.2022.03.038

摘要/Abstract

摘要： 目的由新型冠状病毒(SARS-CoV-2)引起的新型冠状病毒肺炎(COVID-19)疫情已引起世界范围的大流行。呼吸道被认为是SARS-CoV-2感染的主要靶器官。部分COVID-19患者会出现不同程度的肝损伤。本文对COVID-19相关肝损伤发生机制研究进展进行了综述,以期为该病的防治提供参考。

关键词: 新型冠状病毒肺炎, 新型冠状病毒, 肝损伤, 细胞因子风暴

Abstract: Objective The pandemic of COVID-19 has ravaged all over the world. The respiratory tract is considered to be the main target of SARS-CoV-2 infection.Some COVID-19 patients have different degrees of liver injuries. We reviewed the progress on mechanism of liver injuries, so as to provide a therapeutic strategies for COVID-19 patients with liver injuries.

Key words: Corona virus disease 2019, Severe acute respiratory syndrome corona virus 2, Liver injury, Cytokine storm

胡灵溪, 崔坡, 王荣琦. 新型冠状病毒肺炎患者肝损伤机制研究进展^*[J]. 实用肝脏病杂志, 2022, 25(3): 453-456.

Hu Lingxi, Cui Po, Wang Rongqi. Liver injuries in patients with corona virus disease 2019[J]. Journal of Practical Hepatology, 2022, 25(3): 453-456.

参考文献

[1] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版). 中华临床感染病杂志,2020,13(5):321-328.
[2] Xin S, Xu J, Yu Y. Abnormal liver function tests of patients with coronavirus disease 2019 in mainland China:A systematic review and Meta-analysis. J Gastrointest Liver Dis,2020,29(2):219-226.
[3] Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med,2020,383(6):590-592.
[4] Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int,2020,40(9): 2110-2116.
[5] Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol, 2020,73(4): 807-816.
[6] Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression incholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv, 2020,3: 931766.
[7] Kumar A, Kumar P, Dungdung A, et al. Pattern of liver function and clinical profile in COVID-19:A cross-sectional study of 91 patients. Diabetes Metab Syndr, 2020,14(6): 1951-1954.
[8] Huang Q, Xie Q, Shi CC, et al. Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis. Int J Mol Med, 2009,23(6): 717-723.
[9] Yang L, Han Y, Nilsson-Payant BE, et al. Ahuman pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell, 2020,27(1): 125-136.
[10] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020,395(10223): 497-506.
[11] Anirvan P, Narain S, Hajizadeh N, et al. Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19):untangling the knots. Eur J Gastroenterol Hepatol, 2021[ahead of print].
[12] Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. BiochemPharmacol, 2009,78(6): 539-552.
[13] Song JC, Wang G, Zhang W, et al. People’ s Liberation Army Professional Committee of Critical Care Medicine, Chinese Society on Thrombosis and Haemostasis. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res, 2020,7(1): 19.
[14] Paria BC, Vogel SM,Ahmmed GU, et al. Tumor necrosis factor-alpha-induced TRPC1 expression amplifies store-operated Ca2⁺ influx and endothelial permeability. Am J Physiol Lung Cell Mol Physiol, 2004,287(6): L1303-L1313.
[15] Yang X, Yu Y, Xu J, et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered,retrospective, observational study. Lancet Respir Med, 2020,8(5): 475-481.
[16] Chihara R, Nakamoto H, Arima H, et al. Systemic capillary leak syndrome. Intern Med, 2002, 41(11): 953-956.
[17] Duan CY, Zhang J, Wu HL, et al. Regulatory mechanisms, prophylaxis and treatment of vascular leakage following severe trauma andshock. Mil Med Res, 2017,15(4): 11.
[18] Hiltebrand LB, Krejci V, Banic A, et al. Dynamic study of the distribution of microcirculatory blood flow in multiple splanchnic organs in septic shock. Crit Care Med, 2020,28(9): 3233-3241.
[19] Zhong M, Sun A, Xiao T, et al. A randomized,single-blind,group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). MedRxiv, 2020:20066266.
[20] Genctoy G, Altun B, Kiykim AA, et al. TNF alpha-308 genotype and renin-angiotensin system in hemodialysis patients:an effect on inflammatory cytokine levels? Artif Organs, 2005,29(2): 174-178.
[21] Wang R, Alam G, Zagariya A, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol, 2000,185(2): 253-259.
[22] Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited:new roles in inflammation,immunology and aging. EMBO Mol Med, 2010,2(7): 247-257.
[23] Ahmed S, Anirvan P. Reply torheumatologists perspective on coronavirus disease 19:is heparin the dark horse for COVID-19? Clin Rheumatol, 2020,39(7): 2099-2100.
[24] Numaguchi Y, Ishii M, Kubota R, et al. Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. ArteriosclerThrombVasc Biol, 2009,29(12): 2102-2108.
[25] Gromotowicz-Poplawska A, Marcinczyk N, Misztal T, et al. Rapid effects of aldosterone on platelets, coagulation,and fibrinolysis lead to experimental thrombosis augmentation. VasculPharmacol, 2019,122-123: 106598.
[26] Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest, 1995,95(3): 995-1001.
[27] Simões E, Silva AC, Miranda AS, et al. Renin angiotensin system in liver diseases:friend or foe? World J Gastroenterol, 2017,23(19): 3396-3406.
[28] Moshage H. Cytokines and the hepatic acute phase response. JPathol, 1997,181(3): 257-266.
[29] Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. Burns Trauma,2014,2(3): 97-105.
[30] Nguyen-Lefebvre AT, Horuzsko A. Kupffer cell metabolism and function. J EnzymolMetab, 2015,1(1): 101.
[31] Spapen H. Liverperfusion in sepsis, septic shock, and multiorgan failure. Anat Rec (Hoboken), 2008,291(6): 714-720.
[32] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020,8(4): 420-422.
[33] Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19:a case series. E Clin Med, 2020,24: 100434.
[34] Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol, 2020,15(5): 700-704.
[35] Hippensteel JA, LaRiviere WB, Colbert JF, et al.Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol, 2020,319(2): L211-L217.
[36] Alhazzani W, Møller MH, Arabi YM, et al.Survivingsepsis campaign:Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med, 2020,48(6): e440-e469.
[37] Shahrbaf MA,Tabary M, Khaheshi I. The right ventricle in COVID-19 patients. Eur Heart J, 2021,42(6): 559-560.
[38] Grillet F, Behr J, Calame P, et al.Acutepulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology, 2020,296(3): E186-E188.
[39] Zhang XJ, Cheng X, Yan ZZ, et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med, 2018,24(1): 73-83.
[40] Kulkarni AV, Kumar P, Tevethia HV, et al.Systematic review withmeta-analysis:liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther, 2020,52(4): 584-599.
[41] Yip TC, Lui GC, Wong VW, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut, 2021,70(4): 733-742.
[42] Hundt MA, Deng Y, Ciarleglio MM, et al.Abnormal liver tests in COVID-19:A retrospective observational cohort study of 1, 827 patients in a major U.S. hospital network. Hepatology, 2020,72(4): 1169-1176.
[43] Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. JGastroenterol Hepatol, 2020,35(5): 744-748.
[44] Wang W, Xu Y, Gao R, et al.Detection of SARS-CoV-2 indifferent types of clinical specimens. JAMA, 2020,323(18): 1843-1844.
[45] Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol, 2020,92(6): 680-682.
[46] Zhang H, Li HB, Lyu JR, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis, 2020, 96: 19-24.
[47] Skok K, Stelzl E, Trauner M, et al. Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Arch, 2021,478(2): 343-353.
[48] Lamers MM, Beumer J, van der Vaart J, et al.SARS-CoV-2 productively infects human gut enterocytes. Science, 2020,369(6499): 50-54.
[49] Pan L, Mu M, Yang P, et al.Clinicalcharacteristics of COVID-19 patients with digestive symptoms in Hubei,China:A descriptive,cross-sectional,multicenter study. Am J Gastroenterol, 2020,115(5): 766-773.
[50] Amirian ES. Potential fecaltransmission of SARS-CoV-2:Current evidence and implications for public health. Int J Infect Dis, 2020,95: 363-370.
[51] Peiris JS, Chu CM, Cheng VC, et al.Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia:a prospective study. Lancet, 2003, 361(9371): 1767-1772.
[52] Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol, 2011,30(1): 16-34.
[53] Fan Z, Chen L, Li J, et al.Clinicalfeatures of COVID-19-related liver fFunctional abnormality. Clin Gastroenterol Hepatol, 2020,18(7): 1561-1566.
[54] Yang D, Elner SG, Bian ZM, et al.Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res, 2007, 85(4): 462-472.

新型冠状病毒肺炎患者肝损伤机制研究进展^*

Liver injuries in patients with corona virus disease 2019

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张岚, 李妍, 杨宁, 荆晶, 刘爱霞, 黄雨欣, 李伯安. 红细胞分布宽度和中性粒细胞/淋巴细胞比值评估原发性胆汁性胆管炎患者肝损伤临床价值研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 367-370.
[2]	陈业京, 陆清平, 顾少颖. 异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 371-374.
[3]	杨海华, 周聪, 沈国强, 尤晓红, 孟玲. 134例替加环素致药物性肝损伤老年患者临床特征回顾性分析[J]. 实用肝脏病杂志, 2022, 25(3): 375-378.
[4]	刘尚智, 张志强, 李昇锦. 丹栀逍遥散对D-氨基半乳糖/脂多糖诱导的大鼠急性肝损伤保护作用机制研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 179-182.
[5]	尹天泉, 赵程, 刘岩. 参附注射液治疗脓毒症并发急性肝损伤患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(2): 295-296.
[6]	叶超, 李文渊, 李磊, 陈思, 李未, 张开光. 一组不明原因的肝损害患者肝组织病理学诊断研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 38-41.
[7]	姜晓颖, 杨恒, 李明武, 袁保东, 田明, 徐金田, 梅早仙, 潘洪秋, 刘向, 陈晓红, 于德美, 李成俊, 高绪胜, 刘旭晖, 刘建峰, 金龙, 王均琴, 李亮. 甘草酸二铵肠溶胶囊预防初治的肺结核患者药物性肝损害有效性研究[J]. 实用肝脏病杂志, 2022, 25(1): 62-65.
[8]	肖露, 胡弦, 蔡颖珂, 梅凡. 腺苷蛋氨酸联合还原型谷胱甘肽治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 66-69.
[9]	何胜夫, 汪保灿, 范建高, 汪余勤. 胆源性肝损伤临床特征分析及治疗手段探讨[J]. 实用肝脏病杂志, 2022, 25(1): 100-103.
[10]	汤磊, 邹桂舟. 外科疾病导致的胆源性肝损伤诊治现状[J]. 实用肝脏病杂志, 2021, 24(6): 769-771.
[11]	华琪, 陈琦, 游览. 142例抗结核药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 843-846.
[12]	杜云飞, 刘景瑞, 叶飞翔. N-乙酰半胱氨酸联合双环醇治疗抗结核药物所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 847-850.
[13]	管海燕, 杨文斌. 药物性肝损伤患者临床特点及预后分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 713-716.
[14]	李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展^*[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[15]	王丽惠, 张佳祥, 刘双平, 张惠勇, 卢秋燕, 沈培根. 原儿茶酸对刀豆蛋白A所致的免疫性肝损伤小鼠肝组织MDA、NO、SOD和GSH-PX表达的影响[J]. 实用肝脏病杂志, 2021, 24(3): 323-326.